Join Growin Stock Community!

Mediwound ltd.MDWD.US Overview

US StockHealthcare
(No presentation for MDWD)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

MDWD AI Insights

MDWD Overall Performance

MDWD AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

MDWD Recent Performance

0.32%

Mediwound ltd.

0.05%

Avg of Sector

-0.31%

S&P500

MDWD PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

MDWD Key Information

MDWD Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

MDWD Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Price of MDWD

MDWD FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

MDWD Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.90
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
10.61
PB Ratio
4.48
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
18.53%
Net Margin
-98.43%
Revenue Growth (YoY)
6.15%
Profit Growth (YoY)
58.33%
3-Year Revenue Growth
-2.20%
3-Year Profit Growth
-28.33%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.90
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
10.61
PB Ratio
4.48
Price-to-FCF
-
Gross Margin
18.53%
Net Margin
-98.43%
Revenue Growth (YoY)
6.15%
Profit Growth (YoY)
58.33%
3-Year Revenue Growth
-2.20%
3-Year Profit Growth
-28.33%

  • When is MDWD's latest earnings report released?

    The most recent financial report for Mediwound ltd. (MDWD) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MDWD's short-term business performance and financial health. For the latest updates on MDWD's earnings releases, visit this page regularly.

  • What is the operating profit of MDWD?

    According to the latest financial report, Mediwound ltd. (MDWD) reported an Operating Profit of -6.53M with an Operating Margin of -120.19% this period, representing a decline of 28.42% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is MDWD's revenue growth?

    In the latest financial report, Mediwound ltd. (MDWD) announced revenue of 5.43M, with a Year-Over-Year growth rate of 24.66%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does MDWD have?

    At the end of the period, Mediwound ltd. (MDWD) held Total Cash and Cash Equivalents of 59.09M, accounting for 0.63 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does MDWD go with three margins increasing?

    In the latest report, Mediwound ltd. (MDWD) did not achieve the “three margins increasing” benchmark, with a gross margin of 16.5%%, operating margin of -120.19%%, and net margin of -48.8%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess MDWD's profit trajectory and future growth potential.

  • Is MDWD's EPS continuing to grow?

    According to the past four quarterly reports, Mediwound ltd. (MDWD)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.24. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of MDWD?

    Mediwound ltd. (MDWD)'s Free Cash Flow (FCF) for the period is -4.28M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 13.42% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.